Category: Allgemein

Neurofilament light chain (NfL) has become the benchmark biomarker for ALS. But does it capture the full biological complexity of the disease? In our new study published in Neurology: Neuroimmunology & Neuroinflammation, we used the highly sensitive NULISA multiplex platform…

While mutations in the NEK1 gene leading to a loss of the protein were previously the primary known cause of NEK1-associated amyotrophic lateral sclerosis (NEK1-ALS), our study provides the first evidence of a disease-causing missense variant (p.N598S). This rare gene…

The University Hospital of Neurology in Ulm is currently conducting a placebo-controlled study on the efficacy of a high-calorie, high-fat dietary supplement (LIPCAL-ALS II). Twenty-six centers from the German ALS Network (MND-Net) are participating in the study. This investigator-initiated trial…

The successful conclusion of the agreement to conduct an innovative clinical trial marks an important milestone. The trial will evaluate a potential drug for people with C9orf72-ALS—the most common genetic form of the disease. The study’s methodological approach is particularly…

The ERN EURO-NMD, an EU-initiated and funded disease network, is developing a European care pathway for people with ALS as part of the JARDIN Joint Action and is asking patients, family members, and caregivers to participate in a voluntary survey…

We are pleased to officially announce that the ALS Center Ulm is one of the 20 winning teams of the Discovery Award in the Longitude Prize on ALS. The Longitude Prize on ALS is a £7.5 million international funding program…